The bill prioritizes in-person safety checks and stricter medical-waste handling for chemical abortion but does so by restricting telemedicine access and creating criminal/legal risks for providers and suppliers, trading easier access for tighter regulation and potential criminalization.
Women seeking chemical abortion (and patients with chronic conditions) would receive an in-person physical exam before medication is provided, which can identify contraindications and reduce some medical risks.
Hospitals, clinics, and women would face improved medical-waste handling because the bill requires return of biohazard containers, reducing risks from improper disposal.
Women—especially those in rural or clinic-scarce areas—would have reduced access to chemical (medication) abortion because remote/telemedicine provision is restricted, forcing travel or delaying care.
Healthcare providers, manufacturers, distributors, and health systems risk federal criminal liability or a chilling effect on providing or developing legal reproductive-health products and services due to the bill's new offense and broad statutory definitions.
Based on analysis of 2 sections of legislative text.
Introduced March 18, 2026 by Mary E. Miller · Last progress March 18, 2026
Creates a new federal crime to provide or attempt to provide a medication (chemical) abortion in or affecting interstate commerce unless three conditions are met: the provider has physically examined the patient, the provider is physically present at the location of the medication abortion, and the provider gives a disposal "catch kit" and labeled "red bag medical waste" with instructions to return them to the provider. The text defines key terms including "chemical abortion drug" (listing mifepristone and misoprostol and similar drugs), "catch kit," "red bag medical waste," "abortion," and "unborn child." The provided text does not specify criminal penalties, enforcement procedures, exceptions for medical emergencies, effective dates, or funding.